KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic) (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed EPS (Basic) for 6 consecutive years, with -$0.17 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 70.18% year-over-year to -$0.17, compared with a TTM value of -$1.44 through Dec 2025, up 15.29%, and an annual FY2025 reading of -$1.44, up 14.79% over the prior year.
  • EPS (Basic) was -$0.17 for Q4 2025 at Recursion Pharmaceuticals, up from -$0.36 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.42 in Q2 2021 and bottomed at -$1.33 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.38, with a median of -$0.37 recorded in 2022.
  • The sharpest move saw EPS (Basic) surged 147.73% in 2021, then plummeted 190.48% in 2022.
  • Year by year, EPS (Basic) stood at -$0.3 in 2021, then dropped by 0.0% to -$0.3 in 2022, then tumbled by 43.33% to -$0.43 in 2023, then plummeted by 32.56% to -$0.57 in 2024, then soared by 70.18% to -$0.17 in 2025.
  • Business Quant data shows EPS (Basic) for RXRX at -$0.17 in Q4 2025, -$0.36 in Q3 2025, and -$0.41 in Q2 2025.